For the quarter ended September 2024, Heron Therapeutics (HRTX) reported revenue of $32.81 million, up 4.4% over the same period last year. EPS came in at -$0.03, compared to -$0.17 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $36.4 million, representing a surprise of -9.86%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.04 per share when it actually produced a loss of $0.06, delivering a surprise of -50%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Heron Therapeutics, which ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other juris ...

Exhibit 99.1 Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance • Reported positive YTD 2024 Adjusted EBITDA of $1.4 million • Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million • ZYNRELEF ®(bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launch • CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment ...

Core Insights - Heron Therapeutics reported a positive year-to-date 2024 Adjusted EBITDA of $1.4 million and expects Q4 2024 Net Revenue between $37 million and $43 million [1][2] - The company received FDA approval for the ZYNRELEF Vial Access Needle (VAN) in September 2024, with a planned launch in Q4 2024 [1][3] - ZYNRELEF has been included in the CMS Final Rule Non-Opioid Policy for Pain Relief, allowing for separate payment in specific healthcare settings [1][3] Financial Performance - For the three months ended September 30, 2024, Heron reported Net Product Sales of $32.8 million, compared to $31.4 million for the same period in 2023 [26] - The Gross Profit for the same period was $23.4 million, up from $13.2 million year-over-year [26] - The company reported a Net Loss of $4.8 million for the three months ended September 30, 2024, compared to a Net Loss of $25.0 million for the same period in 2023 [26] Product Sales Highlights - Acute Care Franchise Net Product Sales for the three and nine months ended September 30, 2024, were $7.4 million and $19.7 million, respectively, compared to $4.7 million and $12.9 million in 2023 [4] - ZYNRELEF Net Product Sales for the same periods were $6.3 million and $17.1 million, respectively, compared to $4.4 million and $12.0 million in 2023 [4] - APONVIE Net Product Sales for the three and nine months ended September 30, 2024, were $1.1 million and $2.6 million, respectively, compared to $0.3 million and $0.9 million in 2023 [5] Guidance and Future Outlook - The company has narrowed its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses, and Adjusted EBITDA, with updated ranges reflecting improved expectations [3] - The ZYNRELEF VAN is expected to simplify aseptic preparation and reduce withdrawal time significantly, enhancing its market potential [3] - ZYNRELEF will continue to receive separate payment under the CMS policy until at least the end of 2027, with a payment limitation set at $2,267.26 [3]

Wall Street analysts forecast that Heron Therapeutics (HRTX) will report quarterly loss of $0.03 per share in its upcoming release, pointing to a year-over-year increase of 82.4%. It is anticipated that revenues will amount to $36.4 million, exhibiting an increase of 15.8% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 25% to its current level. This demonstrates the covering analysts' collective reassessment of their initial pro ...

SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies.Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a bi ...

SAN DIEGO, Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights.The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avo ...

SAN DIEGO, Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting ("CINV") prevention and APONVIE® for Postoperative Nausea and Vomiting ("PONV") prevention given the temporary shortage of intravenous ("IV") fluids which is expected as t ...

- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release ...